{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06211179",
            "orgStudyIdInfo": {
                "id": "CV027-1070"
            },
            "organization": {
                "fullName": "Bristol-Myers Squibb",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants",
            "officialTitle": "An Open-label, Randomized, Single-dose, Three-way Crossover Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to 5 mg Mavacamten Intact Capsule in Healthy Participants",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-assess-the-relative-bioavailability-of-mg-mavacamten-opened-capsule-administered-via-nasogastric-tube-compared-to-intact-oral-mg-mavacamten-in-healthy-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-04-22",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-04-22",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-18",
            "studyFirstSubmitQcDate": "2024-01-08",
            "studyFirstPostDateStruct": {
                "date": "2024-01-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Bristol-Myers Squibb",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study to assess the relative bioavailability of 5 mg Mavacamten opened capsule administered via nasogastric tube compared to intact oral 5 mg Mavacamten in healthy volunteers."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteers"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 36,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Sequence ABC",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Treatment A: Mavacamten intact oral capsule",
                        "Drug: Treatment B: Mavacamten open capsule in suspension",
                        "Drug: Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)"
                    ]
                },
                {
                    "label": "Sequence BCA",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Treatment A: Mavacamten intact oral capsule",
                        "Drug: Treatment B: Mavacamten open capsule in suspension",
                        "Drug: Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)"
                    ]
                },
                {
                    "label": "Sequence CAB",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Treatment A: Mavacamten intact oral capsule",
                        "Drug: Treatment B: Mavacamten open capsule in suspension",
                        "Drug: Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Treatment A: Mavacamten intact oral capsule",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Sequence ABC",
                        "Sequence BCA",
                        "Sequence CAB"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Treatment B: Mavacamten open capsule in suspension",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Sequence ABC",
                        "Sequence BCA",
                        "Sequence CAB"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Sequence ABC",
                        "Sequence BCA",
                        "Sequence CAB"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum observed concentration (Cmax)",
                    "timeFrame": "Up to 37 days"
                },
                {
                    "measure": "Area under the concentration-time curve from time 0 to the last quantifiable time point (AUC[0-T])",
                    "timeFrame": "Up to 37 days"
                },
                {
                    "measure": "Area under the concentration-time curve from time 0 to 72 hours (AUC[0-72])",
                    "timeFrame": "Up to 37 days"
                },
                {
                    "measure": "Area under the concentration-time curve from time 0 to infinite time (AUC[0-INF])",
                    "timeFrame": "Up to 37 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time of maximum observed plasma concentration (Tmax)",
                    "timeFrame": "Up to 37 days"
                },
                {
                    "measure": "Terminal half-life (T-HALF)",
                    "timeFrame": "Up to 37 days"
                },
                {
                    "measure": "Apparent clearance (CLT/F)",
                    "timeFrame": "Up to 37 days"
                },
                {
                    "measure": "Apparent volume of distribution (Vz/F)",
                    "timeFrame": "Up to 37 days"
                },
                {
                    "measure": "Number of participants with adverse events (AEs)",
                    "timeFrame": "Up to 37 days"
                },
                {
                    "measure": "Number of participants with serious adverse events (SAEs)",
                    "timeFrame": "Up to 37 days"
                },
                {
                    "measure": "Number of participants with vital sign abnormalities",
                    "timeFrame": "Up to 37 days"
                },
                {
                    "measure": "Number of participants with electrocardiogram (ECG) findings",
                    "timeFrame": "Up to 37 days"
                },
                {
                    "measure": "Number of participants with physical examination findings",
                    "timeFrame": "Up to 37 days"
                },
                {
                    "measure": "Number of participants with abnormalities in clinical laboratory evaluations",
                    "timeFrame": "Up to 37 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants must have a body mass index between 18 and 32 kg/m2.\n* Participants must be healthy, as determined by physical examination, vital signs, ECGs, and clinical laboratory assessments.\n* Participants must be willing and able to adhere to the prohibitions and restrictions specified in the protocol.\n\nExclusion Criteria:\n\n* Participants must not have any significant acute or chronic medical illness.\n* Participants must not have any current or recent (within 3 months of study intervention administration) gastrointestinal disease including, but not limited to, bowel obstruction or perforation, gastrointestinal ulcers, esophageal varices, Crohn's disease, diverticulitis, irritable bowel syndrome, ileus, a gastrointestinal tract that is not anatomically intact, dyspepsia, constipation, diarrhea, or vomiting.\n* Participants must not be intolerant or allergic to lidocaine or cetacaine or any type of topical anesthetic.\n\nOther protocol-defined inclusion/exclusion criteria apply",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "60 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMS Study Connect www.BMSStudyConnect.com",
                    "role": "CONTACT",
                    "phone": "855-907-3286",
                    "email": "Clincal.Trials@bms.com"
                },
                {
                    "name": "First line of the email MUST contain the NCT# and Site#",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bristol-Myers Squibb",
                    "affiliation": "Bristol-Myers Squibb",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Worldwide Clinical Trials",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78217",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alan Hand, Site 0001",
                            "role": "CONTACT",
                            "phone": "210-635-1515"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "BMS Clinical Trial Information",
                    "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"
                },
                {
                    "label": "FDA Safety Alerts and Recalls",
                    "url": "http://www.fda.gov/MEDWATCH/safety.htm"
                },
                {
                    "label": "BMS Clinical Trial Patient Recruiting",
                    "url": "https://www.bmsstudyconnect.com/content/studyconnect/us/en/clinical-trials/NCT06211179.html"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-andresearch/disclosure-commitment.html"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}